Trial Profile
A Randomised, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Quality of Life, Safety and Tolerability of Long-term Treatment (24 Weeks) With Prucalopride in Subjects Aged ≥18 Years With Chronic Constipation.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Dec 2022
Price :
$35
*
At a glance
- Drugs Prucalopride (Primary)
- Indications Constipation
- Focus Registrational; Therapeutic Use
- Sponsors Shire; Shire-Movetis NV
- 26 Oct 2022 Results of post hoc pooled analysis from NCT01147926, NCT01424228, NCT01116206, NCT00483886,NCT0048594011 and NCT004881371; evaluating the effect of renal function on the efficacy and safety of prucalopride, presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2022
- 17 Dec 2018 According to a Shire media release, the US FDA has a approved Motegrity (prucalopride), a once-daily, oral treatment option for adults with Chronic Idiopathic Constipation (CIC). This approval is based on the five double-blind, placebo-controlled, randomized, multicenter clinical studies lasting 12 weeks phase 3 (studies 1-5) and one 24 week Phase 4 study (study 6).
- 18 Oct 2018 According to a Shire media release, FDA advisory committee recommended approval of Prucalopride (SHP555) for chronic idiopathic constipation.